Leo Pharma brings hair loss cream into phase II

Dermatology firm Leo Pharma has begun a phase IIa trial of delgocitinib against the hair loss condition frontal fibrosing alopecia.

Photo: Leo Pharma/PR

A new clinical study will assess the safety and efficacy of Leo Pharma’s drug candidate delgocitinib in treating the hair loss condition known as frontal fibrosing alopecia, according to a registration on database Clinical Trials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs